Design of Group IIA Secreted/Synovial Phospholipase A2 Inhibitors: An Oxadiazolone Derivative Suppresses Chondrocyte Prostaglandin E2 Secretion

Group IIA secreted/synovial phospholipase A2 (GIIAPLA2) is an enzyme involved in the synthesis of eicosanoids such as prostaglandin E2 (PGE2), the main eicosanoid contributing to pain and inflammation in rheumatic diseases. We designed, by molecular modeling, 7 novel analogs of 3-{4-[5(indol-1-yl)pentoxy]benzyl}-4H-1,2,4-oxadiazol-5-one, denoted C1, an inhibitor of the GIIAPLA2 enzyme. We report the results of molecular dynamics studies of the complexes between these derivatives and GIIAPLA2, along with their chemical synthesis and results from PLA2 inhibition tests. Modeling predicted some derivatives to display greater GIIAPLA2 affinities than did C1, and such predictions were confirmed by in vitro PLA2 enzymatic tests. Compound C8, endowed with the most favorable energy balance, was shown experimentally to be the strongest GIIAPLA2 inhibitor. Moreover, it displayed an anti-inflammatory activity on rabbit articular chondrocytes, as shown by its capacity to inhibit IL-1β-stimulated PGE2 secretion in these cells. Interestingly, it did not modify the COX-1 to COX-2 ratio. C8 is therefore a potential candidate for anti-inflammatory therapy in joints.

[1]  Heather L Rick,et al.  Varespladib (A-002), a Secretory Phospholipase A2 Inhibitor, Reduces Atherosclerosis and Aneurysm Formation in ApoE−/− Mice , 2009, Journal of cardiovascular pharmacology.

[2]  S. Bryan,et al.  Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. , 2008, Health technology assessment.

[3]  Chang H. Park,et al.  Design of new potent and selective secretory phospholipase A2 inhibitors. Part 5: synthesis and biological activity of 1-alkyl-4-[4,5-dihydro-1,2,4-[4H]-oxadiazol-5-one-3-ylmethylbenz-4'-yl(oyl)] piperazines. , 2008, Bioorganic & medicinal chemistry.

[4]  Nohad Gresh,et al.  Anisotropic, Polarizable Molecular Mechanics Studies of Inter- and Intramolecular Interactions and Ligand-Macromolecule Complexes. A Bottom-Up Strategy. , 2007, Journal of chemical theory and computation.

[5]  Nohad Gresh,et al.  Binding of 5‐phospho‐D‐arabinonohydroxamate and 5‐phospho‐D‐arabinonate inhibitors to zinc phosphomannose isomerase from Candida albicans studied by polarizable molecular mechanics and quantum mechanics , 2007, J. Comput. Chem..

[6]  G. Lambeau,et al.  Inhibition of secreted phospholipase A2. 4-glycerol derivatives of 4,5-dihydro-3-(4-tetradecyloxybenzyl)-1,2,4-4H-oxadiazol-5-one with broad activities. , 2007, Journal of medicinal chemistry.

[7]  J. Avorn,et al.  Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk. , 2006, Arthritis and rheumatism.

[8]  C. Mounier,et al.  Inhibition of secretory phospholipase A2. 1-design, synthesis and structure-activity relationship studies starting from 4-tetradecyloxybenzamidine to obtain specific inhibitors of group II sPLA2s. , 2005, European journal of medicinal chemistry.

[9]  A. Dmitrienko,et al.  LY315920NA/S-5920, a selective inhibitor of group IIA secretory phospholipase A2, fails to improve clinical outcome for patients with severe sepsis* , 2005, Critical care medicine.

[10]  N. Gresh,et al.  Molecular Modeling, Design, and Synthesis of Less Lipophilic Derivatives of 3-(4-Tetradecyloxybenzyl)-4H-1,2,4-oxadiazol-5-one (PMS1062) Specific for Group II Enzyme† , 2005 .

[11]  C. Dong,et al.  Inhibition of secretory phospholipase A2. 2-Synthesis and structure-activity relationship studies of 4,5-dihydro-3-(4-tetradecyloxybenzyl)-1,2,4-4H-oxadiazol-5-one (PMS1062) derivatives specific for group II enzyme. , 2005, Bioorganic & medicinal chemistry.

[12]  S. Myers,et al.  A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis. , 2005, The Journal of rheumatology.

[13]  Pascal Richette,et al.  Peroxisome Proliferator-activated Receptor-γ Down-regulates Chondrocyte Matrix Metalloproteinase-1 via a Novel Composite Element* , 2004, Journal of Biological Chemistry.

[14]  Makoto Murakami,et al.  Recent advances in molecular biology and physiology of the prostaglandin E2-biosynthetic pathway. , 2004, Progress in lipid research.

[15]  J. Pelletier,et al.  Cyclooxygenase-2 and prostaglandins in articular tissues. , 2003, Seminars in arthritis and rheumatism.

[16]  L. Audoly,et al.  The role of prostaglandin E2 receptors in the pathogenesis of rheumatoid arthritis. , 2002, The Journal of clinical investigation.

[17]  A. Romieu,et al.  Total direct chemical synthesis and biological activities of human group IIA secretory phospholipase A2. , 2002, The Biochemical journal.

[18]  J. Pelletier,et al.  The role of cytokines in osteoarthritis pathophysiology. , 2002, Biorheology.

[19]  G. Panayi,et al.  Cytokine pathways and joint inflammation in rheumatoid arthritis. , 2001, The New England journal of medicine.

[20]  J. Grönroos,et al.  Roles of secretory phospholipases A(2) in inflammatory diseases and trauma. , 2000, Biochimica et biophysica acta.

[21]  S. Abramson,et al.  Superinduction of cyclooxygenase-2 activity in human osteoarthritis-affected cartilage. Influence of nitric oxide. , 1997, The Journal of clinical investigation.

[22]  E. Keystone,et al.  Secretory phospholipase A2 as an index of disease activity in rheumatoid arthritis. Prospective double blind study of 212 patients. , 1996, The Journal of rheumatology.

[23]  Simon C Watkins,et al.  Nitric oxide and cartilage metabolism. , 1996, Methods in enzymology.

[24]  Y. Hirata,et al.  Nitric oxide production and inducible nitric oxide synthase expression in inflammatory arthritides. , 1995, The Journal of clinical investigation.

[25]  E. Goetzl,et al.  Specificity of expression and effects of eicosanoid mediators in normal physiology and human diseases 1 , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[26]  E. Dennis.  Diversity of group types, regulation, and function of phospholipase A2. , 1994, The Journal of biological chemistry.

[27]  P. Lawton,et al.  Human extracellular recombinant phospholipase A2 induces an inflammatory response in rabbit joints. , 1991, Journal of immunology.

[28]  W. Dehaen,et al.  Cycloadditions. 45. Annulation of heterocycles via intramolecular nitrile oxide-heterocycle cycloaddition reaction , 1991 .

[29]  M. Murakami,et al.  Exacerbation of rat adjuvant arthritis by intradermal injection of purified mammalian 14‐kDa group II phospholipase A2 , 1990, FEBS letters.

[30]  P. Vadas,et al.  Multiple forms of phospholipase A2 in arthritic synovial fluid. , 1989, Journal of biochemistry.

[31]  R. Kramer,et al.  Structure and properties of a human non-pancreatic phospholipase A2. , 1989, The Journal of biological chemistry.

[32]  K. Inoue,et al.  Purification and characterization of extracellular phospholipase A2 from human synovial fluid in rheumatoid arthritis. , 1989, Journal of biochemistry.

[33]  C. Bon,et al.  A sensitive and continuous fluorometric assay for phospholipase A2 using pyrene-labeled phospholipids in the presence of serum albumin. , 1989, Analytical biochemistry.

[34]  P. Claverie,et al.  Improvements of the continuum model. 1. Application to the calculation of the vaporization thermodynamic quantities of nonassociated liquids , 1988 .

[35]  D. Small,et al.  Lipid digestion and absorption. , 1983, Annual review of physiology.

[36]  Rf Rekker,et al.  THE HYDROPHOBIC FRAGMENTAL CONSTANT; AN EXTENSION TO A 1000 DATA POINT SET , 1979 .

[37]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.